Granted Patent B2

US 12,502,108 · App. 18/205,297 · Granted Dec 23, 2025

Inventors: Naresh C. Bhavaraju (San Diego, CA); Sebastian Böhm (Cardiff, CA); Robert Boock (Carlsbad, CA); Daiting Rong (San Diego, CA); Peter C Simpson (Cardiff, CA)

Assignee: Dexcom, Inc.

A61B5/1495A61B5/14532A61B5/1459A61B5/1473A61B5/14865A61B5/7221A61B5/7246A61B5/7278A61B2562/04

Abstract

Claims (37)

1 . A method for processing data, the method comprising:

receiving sensor data generated by a glucose sensor, wherein the sensor data is indicative of a concentration of glucose in a host;

identifying, using a processor, a post-implantation loss of sensitivity of the glucose sensor by measuring a plurality of time-varying concentration values of a non-glucose analyte and determining if at least one of the plurality of time-varying concentration values of the non-glucose analyte changes more than a predetermined amount;

releasing a bio-active agent configured to minimize reduction or cessation of blood flow to a site surrounding sensor implantation based on the identification of the post-implantation loss of sensitivity; and

processing the sensor data, using the processor, responsive to the identification of the post-implantation loss of sensitivity.

2 . The method of claim 1 , wherein the sensor data comprises data indicative of a signal response to at least one event selected from the group consisting of a signal response to cessation of blood flow to a site surrounding sensor implantation, a signal response to reduction of blood flow to a site surrounding sensor implantation, and a signal response to a vasospastic event.

3 . The method of claim 1 , wherein identifying the post-implantation loss of sensitivity comprises determining a severity of the loss of sensitivity.

4 . The method of claim 3 , wherein processing the sensor data is performed based on the severity of the loss of sensitivity.

5 . The method of claim 1 , wherein identifying the post-implantation loss of sensitivity comprises:

deactivating the glucose sensor for a time period, whereby a product from a catalyzed reaction of glucose and oxygen accumulates over the time period;

activating the glucose sensor and measuring a signal value of the glucose sensor immediately after the time period.

6 . The method of claim 1 , wherein the non-glucose analyte is oxygen and the plurality of time-varying concentration values are oxygen levels or correlated to oxygen transport.

7 . The method of claim 1 , wherein the glucose sensor comprises a first electrode and a second electrode.

8 . The method of claim 7 , wherein the first electrode and the second electrode have different dimensions.

9 . The method of claim 8 , wherein the second electrode is configured to have a dimension that positions the second electrode post-implantation outside of a site affected by cessation or reduction of blood flow.

10 . The method of claim 9 , wherein at least one of the first electrode and the second electrode is configured to minimize tissue trauma from implantation.

11 . The method of claim 7 , further comprising:

determining that the second electrode is positioned outside of a site affected by cessation or reduction of blood flow; and

wherein processing the sensor data responsive to the identification of the loss of sensitivity comprises according more weight to sensor data generated by the second electrode than sensor data generated by the first electrode.

12 . The method of claim 1 , wherein the post-implantation loss of sensitivity is transient.

13 . The method of claim 1 , wherein the post-implantation loss of sensitivity of the glucose sensor is due to a local cessation of blood flow in an implantation area.

14 . A system for detecting glucose comprising:

a sensor configured to be inserted within a host, the sensor configured to generate sensor data indicative of a concentration of glucose in the host;

sensor electronics in communication with the sensor, wherein the sensor electronics include at least one processor configured to:

identify a post-implantation loss of sensitivity of the sensor by measuring a plurality of time-varying concentration values of a non-glucose analyte and determine if at least one of the plurality of time-varying concentration values of the non-glucose analyte changes more than a predetermined amount,

release a bio-active agent configured to minimize reduction or cessation of blood flow to a site surrounding sensor implantation based on the identifying of the post-implantation loss of sensitivity, and

process the sensor data responsive to the identification of the post-implantation loss of sensitivity; and

a display in communication with the sensor electronics, wherein the display is configured to display information about the concentration of glucose in the host.

15 . The system of claim 14 , wherein the sensor comprises a first electrode and a second electrode, wherein the first electrode has different dimensions than the second electrode.

16 . The system of claim 15 , wherein the second electrode is at least partially positioned after implantation in the host outside of a site affected by cessation or reduction of blood flow.

17 . A system for detecting glucose comprising:

a sensor configured to be inserted within a host, the sensor configured to generate sensor data indicative of a concentration of glucose in the host; and

sensor electronics in communication with the sensor, wherein the sensor electronics include at least one processor configured to:

identify a post-implantation loss of sensitivity of the sensor by measuring a plurality of time-varying concentration values of a non-glucose analyte and determine if at least one of the plurality of time-varying concentration values of the non-glucose analyte changes more than a predetermined amount,

release a bio-active agent configured to minimize reduction or cessation of blood flow to a site surrounding sensor implantation based on the identification of the post-implantation loss of sensitivity, and

process the sensor data responsive to the identification of the post-implantation loss of sensitivity.

18 . The system of claim 17 wherein the non-glucose analyte is oxygen.

Assignments (1)

Continuity (6)

References Cited (400)